A share price of Novo Nordisk ADR [NVO] is currently trading at $60.71, down -1.12%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVO shares have gain 9.15% over the last week, with a monthly amount glided 9.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on September 17, 2025, when Berenberg upgraded its rating to a Buy. Previously, Rothschild & Co Redburn upgraded its rating to Buy on September 16, 2025. On September 09, 2025, upgrade upgraded it’s rating to Outperform. BNP Paribas Exane upgraded its rating to a Neutral but stick to its price target of $54 on August 13, 2025. UBS downgraded its rating to a Neutral. HSBC Securities downgraded its rating to Hold for this stock on July 31, 2025, but kept the price target unchanged to $57. In a note dated July 30, 2025, Barclays downgraded an Equal Weight rating on this stock.
Novo Nordisk ADR experienced fluctuations in its stock price throughout the past year between $45.05 and $129.48. Currently, Wall Street analysts expect the stock to reach $52.5 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $60.71 at the most recent close of the market. An investor can expect a potential drop of -13.52% based on the average NVO price forecast.
Analyzing the NVO fundamentals
Trailing Twelve Months sales for Novo Nordisk ADR [NYSE:NVO] were 45.45B which represents 18.96% growth. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.45%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.23, Equity is 0.78 and Total Capital is 0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 59.85 points at the first support level, and at 58.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 61.35, and for the 2nd resistance point, it is at 61.98.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Novo Nordisk ADR [NYSE:NVO] is 0.78. In addition, the Quick Ratio stands at 0.56 and the Cash Ratio stands at 0.09. Considering the valuation of this stock, the price to sales ratio is 4.50, the price to book ratio is 10.20 and price to earnings (TTM) ratio is 16.73.
Transactions by insiders
Recent insider trading involved Novo Nordisk A/S, 10% Owner, that happened on May 30 ’25 when 0.92 million shares were purchased.
